New Delhi, Sep 7 (UNI) Hamdard Laboratories, a progressive research-based health and wellness organisation, on Monday announced that it is going to start clinical trial of its two immunity boosting medicines, to assess their effectiveness in preventing the COVID-19 infection.
The organisation said it has received all the regulatory approvals to begin the proof of concept clinical trial for its Infuza and Kulzam drugs to prevent COVID-19 infection.
A research team from Hamdard Institute of Medical Sciences and Research (HIMSR) is going to start the clinical trial at HAH Centenary Hospital, New Delhi, to evaluate the efficacy of these drugs for the prevention of COVID-19 infection in high-risk subjects.